Nixon Peabody Trust CO Renovo Rx, Inc. Transaction History
Nixon Peabody Trust CO
- $1.11 Billion
- Q2 2024
A detailed history of Nixon Peabody Trust CO transactions in Renovo Rx, Inc. stock. As of the latest transaction made, Nixon Peabody Trust CO holds 97,165 shares of RNXT stock, worth $99,108. This represents 0.01% of its overall portfolio holdings.
Number of Shares
97,165
Previous 97,165
-0.0%
Holding current value
$99,108
Previous $130,000
16.15%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding RNXT
# of Institutions
19Shares Held
1.87MCall Options Held
0Put Options Held
0-
Bank Of The West975KShares$994,5000.27% of portfolio
-
Adar1 Capital Management, LLC Austin, TX355KShares$362,3440.08% of portfolio
-
Geode Capital Management, LLC Boston, MA144KShares$146,7970.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny86.3KShares$88,0420.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA56.7KShares$57,8710.0% of portfolio
About RenovoRx, Inc.
- Ticker RNXT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 9,066,860
- Market Cap $9.25M
- Description
- RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, In...